Cancer clinical trials in the region Occitanie

393 currently recruiting clinical trials
Region Occitanie

Phase 3 Sarcoma and GIST #NCT04307277 #2024-515384-62-00
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Required sarcoma grades
Grade 1 Grade 2 Grade 3
20 recruiting sites
Institut Claudius Regaud
Phase 3 Lung cancer #NCT07218146 #2025-522818-23-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at localized stage
Chemotherapy Bispecific T-cell engager antibodies
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy Bispecific T-cell engager antibodies
12 recruiting sites
Zai Lab (Shanghai) Co., Ltd
Phase 3 Lung cancer #NCT06170788 #2023-503376-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06973187 #2025-522860-34-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
BeOne Medecines
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT07216703 #2025-521514-26-00
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required CPS scores
CPS Positive (>= 1)
Excluded previous treatments at localized stage
Systemic Treatment-Naive
7 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Amyloidosis #NCT07207811 #2024-518899-31-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
19 recruiting sites
Novo Nordisk A/S
Phase 3 Lymphoma #NCT06149286 #2022-503092-28-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma Marginal zone lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
16 recruiting sites
Regeneron Pharmaceuticals
Phase 3 Endometrial cancer #NCT06989112 #2023-508056-19-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma
Required FIGO stages
Stage III Stage IV
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2 MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Radiotherapy Hormone therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Radiotherapy Hormone therapy
Excluded previous treatments at localized stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
10 recruiting sites
Phase 3 Lung cancer #NCT06203210
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Daiichi Sankyo
Phase 3 Breast cancer #NCT06982521 #2025-523083-21-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None 1 2
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy Hormone therapy
Excluded genetic anomalies
AKT PTEN
Excluded previous treatments at localized stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
18 recruiting sites
Relay Therapeutics, Inc.